Very low-dose recombinant factor VIIa for optimized treatment of cardiovascular patients at high risk of hemorrhage

Back

ESC Premium Access

Very low-dose recombinant factor VIIa for optimized treatment of cardiovascular patients at high risk of hemorrhage

Session: Antithrombotics in daily clinical practice

Topic: Thrombosis and coagulation

Speaker: Doctor A. Assmann (Duesseldorf, DE)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Alexander Assmann

Heinrich Heine University Medical School, Duesseldorf (Germany)

0 follower

9 more presentations in this session

Equal safety of rivaroxaban and vitamin K antagonists with regard to the risk of intracranial- and gastrointestinal bleeding in patients with venous thromboembolism - A Danish nationwide study

Speaker: Ms C. Clausen (Hellerup, DK)

Access

Abstract

Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy

Speaker: Doctor C. Crivera (Raritan, NJ, US)

Efficacy and bleeding risk of newer anticoagulants compared to conventional treatment in patients with chronic kidney disease- a meta analysis of randomized controlled trials

Speaker: Assistant Professor K. Prudhvi (Tucson, US)

Management of acute venous thromboembolism in Europe - follow-up data at 1 month from the PREFER in VTE registry

Speaker: Doctor A. Cohen (London, GB)

Red blood cell transfusions increase platelet reactivity in patients treated with dual antiplatelet therapy

Speaker: Miss M. Quillot (Toulouse, FR)

Access the full session

Antithrombotics in daily clinical practice

Speakers: Doctor A. Assmann, Ms C. Clausen, Doctor C. Crivera, Assistant Professor K. Prudhvi, Doctor A. Cohen...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources